Managing adverse effects and complications in completing treatment for hepatitis C virus infection

Topics in Antiviral Medicine

Volumn 20, Issue 4, 2012, Pages 125-128

  Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG COMBINATION; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; METHODOLOGY; PSYCHOLOGICAL ASPECT; RASH; UNITED STATES;

ANTIVIRAL AGENTS; DEPRESSION; DRUG THERAPY, COMBINATION; EXANTHEMA; HEMATOLOGIC DISEASES; HEPATITIS C, CHRONIC; HUMANS; NEW YORK; UNITED STATES;

EID: 84878806819     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence. 2012;6:285-295.
2. Jacobson IM, Everson G, Gordon SC, et al. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. Hepatology. 2007;46(4):315A.
3. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med. 2012;157(2):94-103.
4. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-totreat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991-998.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
6. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024.
7. Poordad F, McCone JJr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
8. Poordad F, Lawitz EJ, Reddy KR, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ ribavirin. [Abstract 1419.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
9. Sulkowski M, Roberts S, Afdhal N, et al. Ribavirin dose modification in treatmentnaive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. [Abstract 1162.] 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
10. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010;52(4):1225-1231.
11. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection. 2008;36(3):250-255.
12. Thevenot T, Mathurin P, Moussalli J, et al. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. J Viral Hepat. 1997;4(4):243-253.
13. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-2236.
14. Birnkrant D. FDA briefing documents on telaprevir NDA 201-917, prepared for the Antiviral Products Advisory Committee, April 1, 2011. http://www.fda.gov/downloads/ AdvisoryCommittees/Committees-MeetingMaterials/Drugs/AntiviralDrugs AdvisoryCommittee/UCM252561.pdf. Accessed October 9, 2012.
15. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56(2):455-63.